Sugi Predict

Sugi Predict / Compounds / SCHEMBL6091

SCHEMBL6091

SCHEMBL6091

OB(O)c1ccc2cc[nH]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 2/20 1.00
▸ TYR P14679 1/20 0.55
▸ AHR P35869 4/20 0.50
▸ CMA1 P23946 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ CYP2A6 P11509 1/20 0.46
▸ GPR84 Q9NQS5 1/20 0.42
▸ TRPA1 O75762 1/20 0.41
▸ ITGB2 P05107 1/20 0.41
▸ ICAM1 P05362 1/20 0.41
▸ ITGAL P20701 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29419532 1.00 ENPP2 (1.00) ENPP2TYRAHRCMA1KDM4E
SCHEMBL1668370 0.85 ENPP2 (0.73) ENPP2TYRAHRCMA1KDM4E
SCHEMBL16687452 0.84 ENPP2 (0.72) ENPP2TYRAHRCMA1KDM4E
SCHEMBL5940 0.83 ENPP2 (0.71) ENPP2TYRAHRCA1CA2
SCHEMBL29444118 0.83 ENPP2 (0.71) ENPP2TYRAHRCA1CA2
SCHEMBL13086505 0.73 ENPP2 (0.58) ENPP2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL25338046 0.73 ENPP2 (0.58) ENPP2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30544060 0.73 ENPP2 (0.58) ENPP2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL14720450 0.72 ENPP2 (0.55) ENPP2TYRAHRCMA1KDM4E
SCHEMBL205203 0.71 CA2 (0.80) ENPP2KDM4EALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2485678-A1 COFERONS AND METHODS OF MAKING AND USING THEM Cornell University (US) 2012-08-15 — — EP claimed
WO-2011043817-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2011-04-14 — — WO claimed
US-7507262-B2 Compositions for oxidatively dyeing keratin fibers and methods for using such compositions THE PROCTER & GAMBLE COMPANY (US) 2009-03-24 — — US claimed
EP-2018146-A2 COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS The Procter and Gamble Company (US) 2009-01-28 — — EP claimed
US-20070209123-A1 Compositions for oxidatively dyeing keratin fibers and methods for using such compositions THE PROCTER & GAMBLE COMPANY 2007-09-13 — — US claimed
WO-2007102126-A2 COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2007-09-13 — — WO claimed
EP-4212523-B1 PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2026-05-06 — — EP disclosed
US-12577248-B2 Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors NANJING RUIJIE PHARMA CO., LTD. (CN) 2026-03-17 — — US disclosed
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 — — US disclosed
US-20250353830-A1 NOVEL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-11-20 — — US disclosed
WO-2025217212-A1 MAC1 INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-16 — — WO disclosed
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-08-05 — — US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 — — EP disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 — — US disclosed
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 — — US disclosed
EP-0595924-B1 PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LAB (US) 1999-04-14 — — EP disclosed
US-5459152-A 3-(pyridin-3-yl)-7-(indol-3-yl)carbonyl-1H,3H-pyrrolo(1,2-c) thiazole derivatives; asthma ABBOTT LABORATORIES (US) 1995-10-17 — — US disclosed
EP-0595924-A4 PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LAB (US) 1994-08-24 — — EP disclosed
EP-0595924-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1994-05-11 — — EP disclosed
WO-1993001813-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1993-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors MERTK, RET, ERBB2 ENPP2 2205/4885TYR 210/4885AHR 656/4885
US-20050020619-A1 Thienopyridine kinase inhibitors ABL1, MAP4K2, MAP4K5 ENPP2 2073/4885TYR 86/4885AHR 3579/4885
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 ENPP2 1807/4885TYR 3752/4885AHR 4553/4885
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK ENPP2 2330/4885TYR 75/4885AHR 3249/4885
US-20250353830-A1 NOVEL COMPOUNDS UQCRB, CCNB3, C5 ENPP2 1313/4885TYR 2021/4885AHR 1827/4885
US-20070209123-A1 Compositions for oxidatively dyeing keratin fibers and methods for using such compositions KRT18, AKR7A2, AKR1C4 ENPP2 4847/4885TYR 17/4885AHR 71/4885
US-12577248-B2 Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors SYK, BTK, TYRO3 ENPP2 1392/4885TYR 62/4885AHR 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.